Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Core Insights - Alvotech, a global biotech company, specializes in the development and manufacture of biosimilar medicines and will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8-10, 2025 [1][2] Company Overview - Alvotech was founded by Robert Wessman and aims to be a leader in the biosimilar market by providing high-quality, cost-effective products and services through a fully integrated approach [3] - The company has launched two biosimilars and has a development pipeline targeting treatments for autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] - Alvotech has established a network of strategic commercial partnerships across various regions, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [3]